Resultados: 29

    COVID-19 treatment guidelines panel: Coronavirus diseases 2019 (COVID-19) treatment guidelines

    The COVID-19 Treatment Guidelines were developed to provide clinicians with guidance on caring for patients with COVID-19. Because clinical information about the optimal management of COVID-19 is evolving quickly, these Guidelines are updated frequently to reflect newly published data and other authorita...

    Substance use: family-based interventions to prevent substance use among youth

    Youth substance use is associated with increased risk for delinquency, academic underachievement, teen pregnancy, sexually transmitted infections, perpetrating or experiencing violence, injuries, and mental health problems (U.S. Department of Health and Human Services 2016). Preventing or delaying substa...

    The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder

    The American Society of Addiction Medicine (ASAM) and the American Academy of Addiction Psychiatry (AAAP) developed this Clinical Practice Guideline on the Management of Stimulant Use Disorder (hereafter referred to as the Guideline) to provide evidence-based strategies and standards of care for the trea...

    Pan-American Guidelines for the Treatment of SARS-CoV-2/COVID-19: a joint evidence-based guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API) [Pré-print]

    Since the beginning of the COVID-19 pandemic, therapeutic options for treating COVID-19 have been investigated at different stages of clinical manifestations. Considering the particular impact of COVID-19 in the Americas, this document aims to present recommendations for the pharmacological treatment of ...

    Novavax COVID-19 vaccine local reactions, systemic reactions, adverse events, and serious adverse events

    Local reactions were reported by the majority of vaccine recipients and at higher rates than placebo recipients (75.3% vs 20.6% after dose 2). Pain/tenderness at the injection site was the most common and most severe local reaction among vaccine recipients and reported more frequently after dose 2 than a...

    VA/DoD clinical practice guideline for the management of headache

    The VA and DoD Evidence-Based Practice Work Group (EBPWG) was established and first chartered in 2004, with a mission to advise the VA/DoD Health Executive Committee “on the use of clinical and epidemiological evidence to improve the health of the population . . .” across the Veterans Health Administ...

    Grading of recommendations, assessment, development, and evaluation (GRADE): Moderna COVID-19 vaccine for persons aged 12-17 years

    A Grading of Recommendations, Assessment, Development and Evaluation (GRADE) review of the evidence for benefits and harms for Moderna coronavirus disease 2019 (COVID-19) vaccine for persons aged 12-17 years was presented to the Advisory Committee for Immunization Practices (ACIP) on June 23, 2022. GRADE...

    Grading of recommendations, assessment, development, and evaluation (GRADE): Moderna COVID-19 vaccine for children aged 6–11 years

    A Grading of Recommendations, Assessment, Development and Evaluation (GRADE) review of the evidence for benefits and harms for Moderna coronavirus disease 2019 (COVID-19) vaccine for children aged 6–11 years was presented to the Advisory Committee for Immunization Practices (ACIP) on June 23, 2022. GRA...

    COVID-19 advisory committee on immunization practices (ACIP) vaccine recommendations

    The Advisory Committee on Immunization Practices (ACIP) provides advice and guidance to the Director of the CDC regarding use of vaccines and related agents for control of vaccine-preventable diseases in the civilian population of the United States. Recommendations made by the ACIP are reviewed by the CD...

    Interim recommendation of the advisory committee on immunization practices for use of the Novavax COVID-19 Vaccine in persons aged ≥18 years: United States, July 2022

    A Grading of Recommendations, Assessment, Development and Evaluation (GRADE) review of the evidence for benefits and harms for Novavax coronavirus disease 2019 (COVID-19) vaccine was presented to the Advisory Committee on Immunization Practices (ACIP) on July 19, 2022. GRADE evidence type indicates the c...